secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-223228
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals enters $250M credit facility, draws $100M upfront
---------------------------------------------------------------------

- $100M Term A Loan drawn Sep 29 2025; up to $250M total available in four tranches.
- Interest: SOFR + 3% floor + 5.50% margin; can decrease 50 bps based on revenue milestones.
- Proceeds fund R&D, product development, and commercialization of neffy.
- Term loans mature 5 years from closing; PIK interest option available for first 2 years.
- Lenders include affiliates of OMERS and RA Capital; RA Capital is largest stockholder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525223228/0001193125-25-223228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525223228/d27880d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-223228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer